Abstract Library

#4541 Prognosis analysis of metastatic rectal neuroendocrine tumour: Liver-directed trans arterial embolisation may play a pivotal role

Introduction: Rectal neuroendocrine tumour (rNET) is prone to metastasis, and distant metastasis is associated with worse prognosis. However, factors influencing the prognosis of metastatic rNET and the recommended treatments remain controversial.

Conference:

Presenting Author: Yang Y

Authors: Yang Y, Chen L, Liu M, Jiang Y, Lin Y,

Keywords: metastatic rectal neuroendocrine tumour, liver metastasis, trans arterial embolisation, inverse probability of treatment weighting, overall survival,

#4491 Expression and clinical significance of IGFBP-3 in pituitary neuroendocrine tumours

Introduction: IGFBP-3 is a regulatory factor highly expressed in pituitary neuroendocrine tumours that may provide reference for the clinical diagnosis and treatment of pituitary neuroendocrine tumours.

Conference:

Presenting Author:

Authors: Hu Y, Yuan C, Tang Y,

Keywords: IGFBP-3, Pituitary neuroendocrine tumour,

#4490 Parietal cell-selective Slc26a9 deletion in mice causes gasdermin D mediates mitochondrial damage and pyroptosis, which is the key event to induce autoimmune gastritis

Introduction: Autoimmune gastritis (AIG) is the basis of gastric malignancy, including neuroendocrine tumour (NET) and gastric cancer (GC). We reported that Slc26a9 is highly expressed in parietal cells (PCs), and its deficiency caused GC.

Conference:

Presenting Author: Liu X

Authors: Ji B, Deng Z, Ma Z, Li T, Tuo B,

Keywords: Slc26a9, autoimmune gastritis, Pyroptosis, gastric mucosal immunity remodelling,

#4481 Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,